Humacyte Inc (NASDAQ: HUMA) kicked off on Tuesday, down -4.49% from the previous trading day, before settling in for the closing price of $4.45. Over the past 52 weeks, HUMA has traded in a range of $2.45-$9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -26.40%. With a float of $103.71 million, this company’s outstanding shares have now reached $119.84 million.
Let’s determine the extent of company efficiency that accounts for 183 employees. In terms of profitability, gross margin is 35.2%, operating margin of -1042.56%, and the pretax margin is -1416.75%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Humacyte Inc is 19.40%, while institutional ownership is 27.92%. The most recent insider transaction that took place on Nov 19 ’24, was worth 7,979. In this transaction President, CEO and Director of this company bought 1,797 shares at a rate of $4.44, taking the stock ownership to the 243,851 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -26.40% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Take a look at Humacyte Inc’s (HUMA) current performance indicators. Last quarter, stock had a quick ratio of 1.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Looking closely at Humacyte Inc (NASDAQ: HUMA), its last 5-days average volume was 2.49 million, which is a jump from its year-to-date volume of 2.42 million. As of the previous 9 days, the stock’s Stochastic %D was 43.25%. Additionally, its Average True Range was 0.37.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 2.29%, which indicates a significant decrease from 9.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.40% in the past 14 days, which was lower than the 90.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.20, while its 200-day Moving Average is $5.42. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $4.43. Second resistance stands at $4.62. The third major resistance level sits at $4.75. If the price goes on to break the first support level at $4.12, it is likely to go to the next support level at $3.99. Now, if the price goes above the second support level, the third support stands at $3.81.
Humacyte Inc (NASDAQ: HUMA) Key Stats
The company with the Market Capitalisation of 546.84 million has total of 125,859K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -110,780 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -39,200 K.
